DUBLIN--(BUSINESS WIRE)--The "Beta-Thalassemia Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Beta-thalassemia in the United States and EU5 (Germany, France, Italy, Spain, and the United Kingdom).
The report provides analysis regarding current treatment practices, emerging drugs like Zynteglo, PTG-300, ACE-011 market share of the individual therapies, and historical, current and forecasted RIE market size from 2017 to 2030, segmented by six major markets.
The report also covers current Beta-thalassemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
The Beta-thalassemia epidemiology chapters provide insights about historical and current Beta-thalassemia patient pool and forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
Beta-thalassemia epidemiology is segmented by the total prevalent cases of Beta-thalassemia minor, diagnosed prevalence of Beta-thalassemia, diagnosed Beta-thalassemia patients by disease type, complications associated with Beta-thalassemia patients. Besides, the report includes a thorough analysis of all segments.
Endocrine complications and Osteoporosis was found in the majority of patients with Beta-thalassemia
According to the report, the total prevalent population of Beta-thalassemia in six major markets was 14,191 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030). The total prevalent cases for Beta-thalassemia were highest in Italy, followed by the United States and Germany.
This segment encloses the detailed analysis of the drugs in the Beta-thalassemia pipeline. It also helps to understand the Beta-thalassemia clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
The clinical management of Beta-thalassemia generally involves blood transfusions, iron chelation, and treatments to alleviate symptoms of iron overload. Potentially curative treatments include bone marrow transplant in selected patients, and gene therapies that aim to partially, if not fully, correct the disorder. The gene therapy, lentiglobin (Zynteglo), which acts via the transplantation of lentiviral-transduced hematopoietic stem cells with increased production of Beta-globin, was approved for the treatment of TDT in the EU in 2019 but is yet to commercially treat its first patient in Germany.
The market size of Beta-thalassemia is expected to increase at a significant CAGR during the study period (2017-2030). Among all the six major markets, the United States accounted for the largest market size. Among EU5 countries, Italy had the largest market size, with USD 77.6 million in 2017, while Spain had the smallest market size of Beta-thalassemia with USD 2.2 million in 2017.
This section focuses on the rate of uptake of the potential drugs in the Beta-thalassemia market or expected to get launched in the market during the study period 2017-2030. The analysis covers Beta-thalassemia market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Zynteglo (bluebirdbio) and Reblozyl (Acceleron/Celgene) are believed to be the most successful therapy amongst all the other expected drug candidates and shall account for the highest market revenue in the coming years.
Pipeline & Development Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics. The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Beta-thalassemia.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Beta-thalassemia domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We have performed the competitive and market Intelligence analysis of the Beta-thalassemia Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
- Expected launch of potential therapies will completely alter the market dynamics of Beta-thalassemia in the coming years. Iron chelating agents mainly rule market size of Beta-thalassemia. The upcoming therapies in each segment are estimated to change the market scenario
- Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
- Acceleron Pharma/Celgene Corporation
- BlueBird Bio
- Protagonist Therapeutics
- Agios Pharmaceuticals
- Ionis Pharmaceuticals
- Vifor Pharma
- Orchard Therapeutics
- Sangamo Therapeutics/Sanofi
- CRISPR Therapeutics/Vertex Pharmaceuticals
- DisperSol Technologies
- Incyte Corporation/Novartis
- Editas Medicine
- La Jolla Pharmaceutical Company
For more information about this drug pipelines report visit www.researchandmarkets.com/r/nb4be5